WELCOME TO Million Health Pharmaceuticals



new type of "targeted" cancer treatment and an integral part of the body's immune system. Naturally the body build antibodies in along with to an antigen which has entered the body and attach to the antigen for destruction by the immune system. An essential cells only aimed by monoclonal antibiotics, they may leads to less toxicity to healthy cell and it is usually treatment recommended only for cancers in which antigens (and the respective antibodies) have been already identified. Mabtas works by linking to the CD20 antigen on normal and malignant B-cells. Hence the body's essential immune security are initiated to attack and kill the marked B-cells. Stem cells i.eyoung cells in the bone marrow which will grow into the various cell types and do not have the CD20 antigen. After treatment,CD20 antigen allows healthy B-cells to multiply


Absorption: Not available Distribution: volume of distribution is 3.1 L Metabolism: Mabtas 500mg metabolized by human antimurine antibody production. Elimination : not available The half life of NHL is 22 days and for RA is 18.0 days, GPA and microscopic polyangitis is 23 days.


Brand : Mabtas
Ingredients : Rituximab
Strength : 500mg
Manufactured : Intas pharmaceuticals
Dosage form : injection

Dosage management

Mabtas is recommended to administer only through intravenous infusion not by IV push or bolus.


First infusion: initially rate of 50 mg/hr is given , in not showing infusion toxicity, rate raised upto 50 mg/hr increments at intervals of 30 min and max of 400 mg/hr. Successive infusion: 100 mg/hr initiated rate , in not showing infusion toxicity, rate raised upto 100 mg/hr increments at intervals of 30 min and max of 400 mg/hr. Premedication with corticosteroids must be considered, if Mabtas combination with CHOP chemotherapy is not given.


Dose is 375 mg/m2 as an IV infusion. Once weeks for 4 or 8 doses administrated for Relapsed treatment Relapsed Retreatment for once weekly for 4 doses administrated. Untreated Previously: given on day 1 of each cycle of chemotherapy, upto 8 doses. In complete or partial response of patient, start with 8 weeks for maintenance following Mabtas in combination with chemotherapy completed then administer 8weeks for 12 doses as a single agent. Once weekly for 4 dose at intervals of 6 months and max of 16 dose for Non – progression (following CVP chemotherapy completion 6 – 8 cycles) On day 1 each cycle of chemotherapy upto 8 infusions for Diffuse large B- cell NHL.


Prior to the administration of Indium-111-(In-111-) Zevalin and Yttrium-90- (Y-90-)Zevalin administer Mabtas infusion about 250 mg/m2 within 4 hours Before toRituxan and Y-90- Zevalin administrate Rituxan and In-111-Zevalin 7–9 days.


Before starting of FC chemotherapy, dose recommended is 375 mg/m2 followed 500 mg/m2 on day 1 of 2-6 cycles every 28 days.


Mabtas is administer with methotrexate combination Mabtas administrating as two dose of 500mg IV infusion 2 weeks separated. When glucocorticoids administered as methyl prednisolone 500mg IV Subsequent course based on clinical evaluation should administer every 24 weeks, but not early than every 16 weeks.


Weekly once for 4 weeks administer Dose of 375 mg/m2 IV infusion While Glucocorticoids combination with methylprednisolone by dose of 1000 mg IV/ day given for 1- 3 days and purse by oral prednisone 1 mg/kg/day are recommended for the treatment of symptoms of serious vasculitis . This drug should intiate within 14 days before or with the starting of Mabtas 500mg and may continue during and after the 4 week course with treatment of Mabtas 500mg drug. Safety and not established for subsequent infusion.


Take an Mabtas amount and diluted to final concentration of 1 mg/ml upto 4 mg/ml as infusion (containing either 0.9% Nacl or 5% dextrose in water). Invert gently the bag and mix the solution. Dispose unused drug left in vial. OVERDOSAGE: If the patients had high dose of Mabtas then seek immediately to the emergency department or poison control help line. Please consult the doctor for further clarification.

Common effects

fever and chills (flu lik symptoms)

Less common side effects

Weakness; nausea; headache; cough; dyspnae; pharyngitis


drug interaction

Mabtas 500mg drug interaction has limited data is available at present. Combination with fludarabine or cyclophosphamide has no effects in pharmacokinetics in CLL patients. Combination with methotrexate had no effects in pharmacokinetics.


Hypersensitivity or murine proteins. Active severe infectons in rheumatoid arthritis Uncontrolled cardiac disease.


Allgeric condition against Mabtas 500mg or any other medication informs your doctor. Concerning your past history of drug used which include in prescription, non-prescription, vitamins &supplements, nutritional products just inform the doctor. While using Mabtas 500mg do not take any vaccination or immunization without taking advice from doctors. Avoid use of Mabtas 500mg if you are pregnant. It will harm the baby unborn, while using Mabtas 500mg use correct birth control to prevent pregnancy and for at least 2 weeks after your treatment ends. Mabtas 500mg may affect the ability to have children in women. Inform your doctor if you planning to pregnant. It is unknown whether Mabtas 500mg passes into breast milk , avoid breast-feed while on Mabtas 500mg treatment.

Quick Contact

Prescription upload

Top Products


Millionpharma.com , a fully licensed and regulated pharmacy medicine, takes all precautions to strictly abide by the laws and regulations set forth in the dispensing of prescription medications. By placing the order for your prescription medicines, you acknowledge and accept the following terms regarding the purchase of any prescription medicines.

Millionpharma.com will not dispense any prescription medication without a valid prescription from a licensed physician.

If you are ordering prescription medication(s), you hereby confirm that you will send us a scanned copy of your valid prescription(s) via email, fax, Whatsapp, or by post, and this prescription shall then be subject to the scrutiny of and approval by our qualified Pharmacists.

The drug information provided in the Millionpharma.com is for informative purposes only and this Website is not intended to provide diagnosis, treatment or medical advice. We are not liable for any adverse effects or harm to you as a result of your reliance on the information in the Website.

Millionpharma.com requires either the User or Customer or the Caregiver to confirm he/she is completely aware of the indications, side effects, drug interactions, effects of missed dose or overdose of the medicines he/she orders from us. It is imperative to seek professional advice from your physician before purchasing or consuming any medicine from Millionpharma.com

At Millionpharma.com , a Caregiver can order prescription medicines on your behalf.


This information should not be used to decide whether or not to take this Product or any other medicine. Only the healthcare provider has the knowledge and training to decide which medicines are right for a specific patient. This information does not endorse any medicine as safe, effective, or approved for treating any patient or health condition. This is only a brief summary of general information about this Product . It does NOT include all information about the possible uses, directions, warnings, precautions, interactions, adverse effects, or risks that may apply to this product. This information is not specific medical advice and does not replace information you receive from the healthcare provider. You must talk with the healthcare provider for complete information about the risks and benefits of using this product.